Hyloris Pharmaceuticals SA | Mid-cap | Healthcare
€6.48
0.93%
| Hyloris Stock Comparison:
Hyloris vs Argenx SEHyloris vs UCB S.AHyloris vs Onward Medical N.VHyloris vs European MedicalHyloris vs Celyad Oncology S.AHyloris vs BEL 20 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2020

Income Metrics

Revenue 19.0K
Gross Profit -70.0K -368.42%
Operating Income -2.4M -12,468.42%
Net Income -2.2M -11,378.95%

Balance Sheet Metrics

Total Assets 41.3M
Total Liabilities 9.2M
Shareholders Equity 32.1M
Debt to Equity 0.29

Cash Flow Metrics

Operating Cash Flow -928.0K
Free Cash Flow 2.3M

Revenue & Profitability Trend

Hyloris Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i8.5M2.1M900.0K3.1M175.0K
Cost of Goods Sold i227.0K93.0K94.0K107.0K145.0K
Gross Profit i8.2M2.0M806.0K3.0M30.0K
Gross Margin % i97.3%95.5%89.6%96.5%17.1%
Operating Expenses
Research & Development i10.3M14.4M10.3M5.1M3.4M
Selling, General & Administrative i6.2M5.5M3.5M2.9M2.2M
Other Operating Expenses i10.0K-12.0K5.8M-
Total Operating Expenses i16.5M20.0M13.8M13.7M5.6M
Operating Income i-6.4M-15.8M-11.5M-10.3M-5.6M
Operating Margin % i-75.3%-759.3%-1,278.7%-334.2%-3,174.9%
Non-Operating Items
Interest Income i901.0K869.0K67.0K32.0K543.0K
Interest Expense i77.0K52.0K219.0K556.0K992.0K
Other Non-Operating Income-----
Pre-tax Income i-6.3M-15.4M-11.9M-11.3M-7.1M
Income Tax i004.0K297.0K1.0K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-6.3M-15.4M-11.9M-11.6M-7.1M
Net Margin % i-75.0%-736.9%-1,322.9%-374.0%-4,082.9%
Key Metrics
EBITDA i-4.9M-15.0M-12.0M-10.6M-5.7M
EPS (Basic) i-€-0.55€-0.43€-0.45€-0.33
EPS (Diluted) i-€-0.55€-0.43€-0.45€-0.33
Basic Shares Outstanding i-28000374271989252583263221818814
Diluted Shares Outstanding i-28000374271989252583263221818814

Income Statement Trend

Hyloris Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i23.6M30.4M33.5M50.0M64.4M
Short-term Investments i--10.0M528.0K7.0K
Accounts Receivable i4.9M3.6M4.1M2.3M48.0K
Inventory i-----
Other Current Assets---1.1M2.0M
Total Current Assets i29.7M35.3M49.8M54.0M66.6M
Non-Current Assets
Property, Plant & Equipment i340.0K429.0K176.0K122.0K24.0K
Goodwill i3.8M3.8M3.6M2.9M2.4M
Intangible Assets i3.8M3.8M3.6M2.9M2.4M
Long-term Investments-----
Other Non-Current Assets-1.0K-1.0K1.7M-
Total Non-Current Assets i11.6M12.4M10.9M9.5M2.6M
Total Assets i41.3M47.7M60.7M63.4M69.2M
Liabilities
Current Liabilities
Accounts Payable i3.2M3.2M2.3M2.6M1.6M
Short-term Debt i326.0K241.0K138.0K65.0K455.0K
Current Portion of Long-term Debt-----
Other Current Liabilities----1.0K
Total Current Liabilities i7.2M6.8M5.8M15.0M2.1M
Non-Current Liabilities
Long-term Debt i1.5M1.5M747.0K109.0K8.0M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities--1.0K-1.0K-
Total Non-Current Liabilities i2.0M1.9M1.0M410.0K8.0M
Total Liabilities i9.2M8.6M6.8M15.4M10.1M
Equity
Common Stock i140.0K140.0K140.0K129.0K129.0K
Retained Earnings i-86.5M-80.8M-65.4M-54.8M-43.2M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i32.1M39.1M53.9M48.1M59.1M
Key Metrics
Total Debt i1.8M1.8M885.0K174.0K8.4M
Working Capital i22.5M28.5M44.0M39.0M64.5M

Balance Sheet Composition

Hyloris Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-6.3M-15.4M-11.9M-11.6M-7.1M
Depreciation & Amortization i-----
Stock-Based Compensation i-584.0K540.0K560.0K576.0K485.0K
Working Capital Changes i-1.9M29.0K-865.0K-1.6M1.4M
Operating Cash Flow i-9.6M-15.4M-11.9M-12.4M-3.8M
Investing Activities
Capital Expenditures i-29.0K-298.0K-101.0K-107.0K0
Acquisitions i----1.3M0
Investment Purchases i-0-10.5M-1.2M-10.0K
Investment Sales i010.0M522.0K216.0K0
Investing Cash Flow i-29.0K9.7M-10.1M-2.3M-10.0K
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i139.0K51.0K0-18.2M
Debt Repayment i-40.0K0-7.4M-62.0K-8.1M
Financing Cash Flow i99.0K51.0K9.8M-62.0K69.4M
Free Cash Flow i-7.2M-13.6M-13.8M-12.3M-5.2M
Net Change in Cash i-9.5M-5.7M-12.2M-14.8M65.6M

Cash Flow Trend

Hyloris Key Financial Ratios

Valuation Ratios

Forward P/E -28.80
Price to Book 5.64
Price to Sales 18.94

Profitability Ratios

Profit Margin -64.98%
Operating Margin -47.62%
Return on Equity -17.81%
Return on Assets -8.94%

Financial Health

Current Ratio 4.15
Debt to Equity 5.65
Beta 0.30

Per Share Data

EPS (TTM) €-0.23
Book Value per Share €1.15
Revenue per Share €0.35

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
hyl184.8M-5.64-17.81%-64.98%5.65
Argenx SE 36.2B33.975.7824.72%41.03%0.71
UCB S.A 35.1B26.923.6214.30%19.45%29.72
Onward Medical N.V 185.9M-5.313.87-108.28%71.43%31.40
European Medical 19.5M35.381.885.40%1.14%191.98
Celyad Oncology S.A 16.2M-0.2232.50-170.92%0.00%177.10

Financial data is updated regularly. All figures are in the company's reporting currency.